Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study

The Lancet Respiratory Medicine 2026

View at publisher
Authors: Jorge Máspero, Ian D Pavord, Michael E Wechsler, William Busse, Tanya M. Laidlaw, Robert Mróz, Tian Liu, Vincent Mikol, Benjamin T. Suratt, Jessica Gereige, Leda Mannent, Renata Martincova
DOI: 10.1016/s2213-2600(25)00439-4
Cited by: 6
References: 31

Fields of Study & Subjects

Chronic Lymphocytic Leukemia Research Galectins and Cancer Biology Lung Cancer Treatments and Mutations

Publication details

Journal / source
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Volume
14
Issue
5
Pages
405–416
Publication date
3 April 2026
Language
EN